Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Market Cap	2.78T +224.7%
Revenue (ttm)	7.75B -44.9%
Net Income	-21.89B
EPS	-728.12
Shares Out	30.38M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	835,096
Average Volume	657,909
Open	96,100
Previous Close	91,500
Day's Range	91,500 - 97,000
52-Week Range	25,450 - 179,900
Beta	1.26
RSI	35.74
Earnings Date	Mar 26, 2026

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2002
• Employees: 18
• Stock Exchange: KOSDAQ
• Ticker Symbol: 140410

Financial Performance

In 2024, Mezzion Pharma's revenue was 8.61 billion, a decrease of -72.85% compared to the previous year's 31.72 billion. Losses were -19.48 billion, 53.0% more than in 2023.